Krystal Biotech, Inc. (KRYS)

SEC fundamentals · as filed in 10-Q FY2026, period ended Jun 30, 2026 · updated Oct 7, 2026

Verified against EDGAR
Total Assets
$1.50B
Stockholders' Equity
$1.36B
Cash & Equivalents
$427.7M
Long-Term Debt
—

as filed in 10-Q FY2026, period ended Jun 30, 2026 · View filings on EDGAR ↗

In its 10-Q for the period ended Jun 30, 2026, Krystal Biotech, Inc. reported revenue of $119.2M, net income of $54.8M, and total assets of $1.50B. Every figure below is taken directly from Krystal Biotech, Inc.'s SEC filings: each links to the source document on EDGAR.

Revenue trend

Revenue · FY2021–FY2025 · as reported

$389.1M$124.6M-$140.0M
FY2021FY2022FY2023FY2024FY2025
Revenue$389.1MNet income$204.8M
FY2021 revenue
$0
FY2025 revenue
$389.1M

Revenue and net income by fiscal year

As reported in each year’s annual filing · USD

Fiscal yearRevenueNet income
FY2025$389.1M$204.8M
FY2024$290.5M$89.2M
FY2023$50.7M$10.9M
FY2022$0-$140.0M
FY2021$0-$69.6M
FY2020—-$32.2M
FY2019—-$19.1M
FY2018—-$10.9M
FY2017—-$7.9M
FY2016—-$1.1M

Recent SEC filings

Filed by the registrant · newest first · insider forms and holder schedules not included

FormFiledSource
8-KOct 15, 2026on EDGAR ↗
8-KAug 3, 2026on EDGAR ↗
10-QAug 3, 2026on EDGAR ↗
8-KJul 21, 2026on EDGAR ↗
8-KMay 20, 2026on EDGAR ↗
10-QMay 4, 2026on EDGAR ↗
8-KMay 4, 2026on EDGAR ↗
DEF 14AApr 3, 2026on EDGAR ↗
8-KFeb 17, 2026on EDGAR ↗
10-KFeb 17, 2026on EDGAR ↗

All filings on EDGAR ↗

Balance Sheet

as of Jun 30, 2026 · 10-Q

Total Assets$1.50Bsource ↗
Stockholders’ Equity$1.36Bsource ↗
Cash & Equivalents$427.7Msource ↗
Long-Term Debt—source ↗

Income Statement

10-Q (quarterly) · period ended Jun 30, 2026

Revenue$119.2Msource ↗
Net Income$54.8Msource ↗
Operating Income$58.4Msource ↗
Gross Profit—source ↗
Cost of Revenue—source ↗
R&D Expense$14.5Msource ↗

Per Share & Cash Flow

10-Q (quarterly) · period ended Jun 30, 2026

EPS (diluted)$1.79source ↗
EPS (basic)$1.85source ↗
Shares Outstanding29.6Msource ↗
Cash from Operations$74.8Msource ↗
Cash from Financing$15.1Msource ↗
Cash from Investing-$161.6Msource ↗

Insider activity

Form 4 open-market activity, last 180 days

Buys
0
Sells
58
Net shares
-126.6K

Restatement history

Point-in-time

1 of 231 annual fact-keys were materially restated between filings: what Krystal Biotech, Inc. first reported differed from what it later filed. We keep every vintage of every annual figure, each keyed to its EDGAR accession.

See each original-vs-restated value, and query any company as of any past date, with the point-in-time API.

Deeper fundamentals

A free API key reaches KRYS’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.

Programmatic access

Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.

These fundamentals, as filed
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/KRYS

MCP tool: get_sec_fundamentals ticker=KRYS

The same figures as they were known on any past date
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/KRYS/as-of/YYYY-MM-DD

MCP tool: get_asof_fundamentals ticker=KRYS as_of=YYYY-MM-DD

Fiscal-year trajectory: revenue, margins, free cash flow
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/KRYS/history

MCP tool: get_fundamentals_history ticker=KRYS

Leverage, liquidity, margin and return ratios
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/financial-health/KRYS

MCP tool: get_financial_health ticker=KRYS

Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.